HHRI Media Coverage
zAmya Theater brings people with (and without) experience around homelessness together around theater, community, advocacy and social justice. For this production, zAmya worked with Dr. Kate Diaz Vickery Diabetes + Homelessness Research Team from Hennepin Healthcare Research Institute. They did a staged reading of the play at the Capri Theatre in North Minneapolis. Dr. Vickery has been working on research and prevention of diabetes, especially with people experiencing homelessness for many years. Her team went to a zAmya production before the pandemic and a lightbulb popped. She realized that theatre might be an effective way to get the message to the target market. The show was much more engaging and memorable than a brochure.
Read the article on Mostly Minnesota.
Imagine you’ve been on a waiting list for a new liver for years. When you learned you would need an organ transplant, your head was spinning. You were sent to a transplant center, where you underwent a lengthy evaluation process to determine your eligibility to be placed on the waiting list for a new liver. Three and a half years later, your phone rings in the middle of the night. It’s your transplant center, calling to offer you a liver! Finally, the moment you’ve been waiting for. But wait — the nurse coordinator on the other end of the line is explaining that the organ you’re being offered came from someone who died of a drug overdose, although test results don’t show any signs of infection. “The current process for matching an organ to a patient isn’t very patient-friendly,” says Cory Schaffhausen, PhD, a researcher at Hennepin Healthcare Research Institute, assistant professor at University of Minnesota Medical School, and human-centered design engineer at the Scientific Registry of Transplant Recipients (SRTR), a data registry located at Hennepin Healthcare that analyzes outcomes for organ transplant donors and recipients across the U.S. He set out to change that in 2020 with his research and design project, Embedding Human-Centered Design and Learning Health System Research in the Transplantation System.
Read the story on UMN.
Things have looked up for U.S. kidney transplant recipients over the past few decades, according to a review article. In adult kidney transplant recipients, the total number of transplants from living and deceased donors in the U.S. jumped from 45,008 in 1996-1999 up to 76,885 in 2016-2019, reported Sundaram Hariharan, MD, of the University of Pittsburgh School of Medicine, and colleagues. This uptick was largely driven by a rise in the number of transplants from deceased kidney donors, from 29,823 in 1996 to 53,139 in 2019, they stated in the New England Journal of Medicine.
Read the article on MedPage Today.
An ongoing COVID-19 clinical trial studying the outpatient use of metformin, a generic medication for type 2 diabetes, has expanded and will now be the nation’s first to include fluvoxamine, an antidepressant, and ivermectin, an antiparasitic, as possible treatment options to prevent hospitalization and “long COVID.” Hennepin Healthcare in Minneapolis is a participating Clinical trial site.
Read the article on The Gilmer Mirror.
The University Hospital Center for Advanced Liver Diseases and Transplantation program was rated the top program for the second consecutive evaluation period for one-year survival rates in the Tri-state area by the Scientific Registry of Transplant Recipients. The program led by Rutgers New Jersey Medical School physicians has an estimated one-year survival rate of nearly 99 percent. Since 1989, the center for Advanced Liver Diseases and Transplantation has completed more than 1,500 liver transplant surgeries. In the past two years, the center performed over 80 transplants. The Scientific Registry of Transplant Recipients is a federally supported program for organ transplantation in the country. It is operated by the Chronic Disease Research Group and is a division of the Hennepin Healthcare Research Institute.
Read the article on Tap into Newark.
For the second consecutive evaluation period, the Scientific Registry of Transplant Recipients (SRTR) has rated the liver transplant program at Newark’s University Hospital Center for Advanced Liver Diseases and Transplantation, as the regional leader in one-year survival rates. The Center is led by the nationally-recognized physicians at Rutgers New Jersey Medical School. With an estimated one-year survival rate of 98.75%, the Center was rated as one of the top centers from all hospitals in the New York Tri-State area of New Jersey, New York and Connecticut. The SRTR, operated by the Chronic Disease Research Group, a division of the Hennepin Healthcare Research Institute, is a federally supported program. Evaluations of liver transplant programs are released twice a year, in January and July.
Read the article on New Jersey Business.
The number of patients receiving treatment for end-stage kidney disease in April was 0.6% lower than a year ago, the first such year-to-year drop in patient census since 1980, a new study shows. “Between week 1 of 2015 and week 13 of 2020, the numbers of dialysis and transplant patients steadily increased, with little deviation from quadratic trends,” Eric D. Weinhandl, PhD, MS, and colleagues from the Chronic Disease Research Group at the Hennepin Healthcare Research Institute in Minneapolis, wrote.
Read the article on Healio.
Black patients and patients with limited English language proficiency were more likely to get a COVID-19 test initiated in an in-person healthcare setting than via telehealth, according to data published in JAMA Network Open that emphasizes how social determinants of health affected COVID-19 testing access during the pandemic. The report, completed by researchers from the University of Minnesota and Hennepin Healthcare Research Institute (HHRI), particularly investigated health disparities in some of the emerging care access modalities made prominent by the COVID-19 crisis. This isn’t because getting an ED-based test is better or worse care; rather, the disparity likely stems from the already poor health experienced by the individual admitted for inpatient care. This demonstrates how barriers to various care access modalities can affect downstream health outcomes, according to Peter Bodurtha, a data scientist with HHRI who worked on the study.
Read the article on Patient Engagement Hit.
The opioid epidemic led to a record number of drug overdoses in the United States last year. The spike is happening in Minnesota, too. Just under 800 Minnesotans died from drug overdoses in 2019. More than 1,000 died last year — a 35% jump. When a lot of the world was shutting down due to the pandemic, the counselors at the Alliance Wellness Clinic in Bloomington stayed open to help people struggling with opioid addiction. Yussuf Shafie owns the clinic. Dr. Gavin Bart, an addiction medicine specialist at Hennepin Healthcare and HHRI researcher, says deadly overdoses from illicitly manufactured opiates like fentanyl are way up in Minnesota.
Read the story on CBS Minnesota.
A recent study from researchers at the University of Minnesota and Hennepin Healthcare Research Institute (HHRI) is among the first to examine how different socio-demographic groups used telehealth, outpatient (i.e., clinic), emergency department and inpatient (i.e., hospital) care to test for SARS-CoV-2, the virus that causes COVID-19. Their findings were recently published in JAMA Network Open. The study was led by U of M School of Public Health along with others from Hennepin Healthcare and HHRI. Researchers included Tyler Winkelman, MD, MSc, and HHRI Data Scientist Peter Bodurtha. The team analyzed anonymous electronic health record data for people with symptoms of viral illness who received SARS-CoV-2 testing at Hennepin Healthcare, a large safety-net health system in Minneapolis. The researchers also added that the inequities could be partially explained by clinician and clinic variations in telehealth use. “Without structural reforms, rapid implementation of telehealth and other new services may exacerbate inequities in access to care, particularly if these investments come at the expense of other care sites,” said Bodurtha.
Read the article on UMN.
A Penn Medicine study found that Medicaid expansion helped increase access to medication for opioid use disorder, despite some existing limitations to widespread access. The study, led by Perelman School of Medicine fellow Utsha Khatri, found that Medicaid expansion correlates to significant improvements in accessing medication for OUD. Previous clinical studies have found that medications for opioid use disorder result in more effective outcomes for retention in treatment, reduced illicit opioid use, decreased opioid-related overdose rates, and serious acute care. “Medicaid alone will not entirely close gaps in care between people with and without criminal justice involvement. Additional work is needed to understand key drivers of the persistent disparities we identified,” senior author Tyler Winkelman, Co-Director of the Health, Homelessness, and Criminal Justice lab at the Hennepin Healthcare Research Institute, told Penn Medicine News.
Read the article on The Daily Pennsylvanian.
A record number of Hennepin County residents fatally overdosed from opioids or methamphetamines last year, with an alarming spike in deaths from fentanyl, a powerful synthetic painkiller that can be lethal even in tiny doses. Hennepin County recorded 285 opioid-related deaths for the year, with nearly all involving at least trace amounts of fentanyl. That is up from 170 opioid deaths the year before. Methamphetamine overdoses reached a record 116 in the county last year. Methamphetamine use surged during the pandemic because the drug is more accessible and cheaper to buy, said Dr. Tyler Winkelman, a physician who treats inmates with substance abuse issues at the Hennepin County jail. With opioid and methamphetamine abuse worsening in Hennepin County, COVID-19 has scared people away from seeking treatment, he said.
Read the article on Star Tribune.
The immune system overreaction to COVID-19 has become a key target for therapeutic research, including a new trial at the University of Minnesota using stem cells to try to suppress the body’s response to infection and repair the damage it causes. A COVID-19 Treatment Guidelines team formed by the National Institutes of Health has reviewed evidence for using mesenchymal stem cells to treat this hyperimmune response but does not recommend them outside of clinical trials. “It’s very much not ready for clinical implementation and clinical use,” said Dr. Jason Baker, a Hennepin Health doctor who is part of the NIH review team. “There is potential, but it very much needs to be proven.”
Read the story on Star Tribune.
Preliminary research by Mayo Clinic shows that high-dose plasma therapy is correlated with fewer deaths in patients with severe COVID-19. A 10 percentage point difference in deaths was found when comparing hospitalized COVID-19 patients who received donor plasma with high concentrations of virus-fighting antibodies compared with those who received lower concentrations, Mayo reported. HCMC in Minneapolis and Regions routinely screen COVID-19 patients shortly after admission for their interest and eligibility for convalescent plasma. “We’re all kind of waiting for more standard products to come out where you know how much antibody that someone is getting,” said Dr. Anne Frosch, who is leading HCMC’s COVID-19 convalescent plasma program.
Read the story on Star Tribune.
Published in the peer-reviewed journal Health Affairs, “Practice and Policy Reset Post-COVID-19: Reversion, Transition or Transformation?” was written by Christine Sinsky, MD, vice president of professional satisfaction at the AMA, and AMA member Mark Linzer, MD, director of the Institute for Professional Work Life at Hennepin Healthcare and professor of medicine at the University of Minnesota in Minneapolis. The commentary examines actions by regulators and payers to modify policies and lift administrative and technological burdens that allow health professionals to meaningfully care for patients with COVID-19. Most ambulatory visits are now being conducted through telehealth and in places where COVID-19 is surging, there is a need for all hands-on deck. This has led health professionals to take on new roles to meet the demand. To support these changes, the Center for Medicare and Medicaid Services (CMS) and other regulators and payers have modified longstanding policies, eliminated some nonessential administrative tasks and reduced preexisting constraints on team-based care.
Read the story on AMA.
When Jennifer Bennetch noticed boarded-up houses seemingly everywhere in North Philadelphia, she began documenting them. She noted their addresses and followed up to see the status of the properties: whether new residents had moved in, or if the houses were being renovated or brought to auction. She ultimately found that the owner of the properties, the Philadelphia Housing Authority (PHA), had no plans but to let them sit idle—so, in March, she quietly began moving in families. Moms 4 Housing has framed their fight for housing as a human right; their claim to secure and affordable housing is shaped through their identity as mothers with children in their care. Their demand for a home in which they can securely dwell and raise their family is a core component of reproductive justice, defined by SisterSong as the “right to maintain personal bodily autonomy, have children, not have children, and parent them in safe and sustainable communities.” Housing functions as an “anchor that families require to build security in terms of shelter, food, education, childcare, and employment,” Dr. Diana Cutts, a pediatrician and co-lead principal investigator for the research group Children’s HealthWatch, told Rewire.News.
Read the story on Rewire News.
Medical experts have for weeks tested the degree to which anti-viral treatments such as hydroxychloroquine and remdesivir can prevent the coronavirus from gaining ground inside a patient’s body. With a boost from Bill Gates, two doctors at the University of Minnesota Medical School are challenging the medical community to try a different approach — treatment studies involving common high-blood pressure medications. “This is different than doing what most of the other clinical trials are trying to do right now,” said Dr. Michael Puskarich, associate professor in the Department of Emergency Medicine at the University and emergency physician at Hennepin Healthcare. “We’re looking at more of the downstream consequences of the virus.” The doctors have launched two multi-site inpatient and outpatient clinical trials involving the drug Losartan.
Read the story on Pioneer Press.
Hennepin Healthcare has launched two clinical trials for a drug to see if it will help COVID-19 patients. The trials are being doing through the Hennepin Healthcare Research Institute. “The clinical trials will help to determine if remdesivir is a safe and effective drug that can improve outcomes for patients diagnosed with COVID-19 here at Hennepin Healthcare and in the broader community,” principal investigator Dr. Jason Baker said.
Read the story on CBS Minnesota.
A new drug is being called a ‘ray of hope’ in treating COVID-19. "This is a medicine that directly attacks the virus," said Jason Baker, MD, MS, Hennepin Healthcare’s infectious disease director. Doctors at the Hennepin Healthcare Research Institute hope to enroll about 1,000 patients now hospitalized with moderate or severe COVID-19.
Read the story on MinnPost.
Initially, remesivir was developed to treat ebola but failed to stop that virus. But now it has been found that the drug affects other forms of coronavirus, including SARS and MERS. “It turned out to be very active against that virus in the lab, so it quickly escalated to human studies for the COVID outbreak,” said HHRI’s Principal Investigator Jason Baker, MD, MS. The drug, which has not been approved by the Food and Drug Administration, is administered through an IV and works by preventing the virus from growing.
Read the Vaaju story.
Remdesivir was originally developed to treat Ebola, but was unable to stop this virus. However, the drug has been found to affect other forms of the coronavirus, including SARS and MERS. “It was found to be very active in the laboratory against this virus, and it was therefore quickly expanded to human studies for the COVID outbreak,” said HHRI’s Principal Investigator Jason Baker, MD, MS. Hennepin Healthcare wants to determine if the drug is useful and safe.
Read the NewsBeezer story.
A new drug is being called a "ray of hope" in treating COVID-19. “This is a medicine that directly attacks the virus,” said Jason Baker, MD, MS, Hennepin Healthcare’s infectious disease director. “Rendesivir is one of the only direct anti-viral medicines that’s being studied in the context of COVID-19.” Doctors at the Hennepin Healthcare Research Institute hope to enroll about 1,000 patients now hospitalized with moderate or severe COVID-19.
Read the story on KSTP.
Researchers at Hennepin Healthcare are joining sites across the world in studying a drug that could help patients who have COVID-19. The clinical trials now underway at Hennepin Healthcare will study hospitalized patients with severe and moderate cases of COVID-19. They'll get an IV of remdesivir, an experimental antiviral drug. It was created to treat Ebola, but wasn't effective for that disease. "It actually blocks the virus' ability to reproduce itself genetically. It blocks that replication," said Dr. Jason Baker, the Director of Infectious Disease at Hennepin Healthcare.
Read the story on KARE 11.
Hennepin Healthcare has announced it has launched two clinical trials to study the safety of using an antiviral drug created for Ebola patients on those with the coronavirus. The Hennepin Healthcare Research Institute (HHRI), the medical research organization based at Hennepin County Medical Center, says it will be trialing the drug Remdesivir on patients with moderate or severe COVID-19. "We are proud to be a site that’s conducting research on this investigational treatment,” said HHRI’s Principal Investigator Jason Baker, MD, MS.
Read the story on Bring Me The News.
A drug that is showing some early success in treating severe cases of COVID-19 is now being studied in trials by Hennepin Healthcare. The Hennepin Healthcare Research Institute has launched two trials to study the safety of remdesivir. The drug had previously been tested on humans for an Ebola treatment. It has also shown some success with in vitro and animal models against other coronaviruses strains including MERS and SARS.
Read the story on FOX 9.
Hennepin Healthcare and Mayo Clinic are participating in an international clinical trial on using the drug remdesivir to treat hospitalized COVID-19 patients. Hennepin Healthcare in Minneapolis said Friday it will have 70 patients in part of a 1,000-patient worldwide study of the potential antiviral treatment developed by Gilead Sciences in California. Mayo Clinic in Rochester is also among the 133 study locations. Remdesivir showed "antiviral activity" against other coronaviruses MERS and SARS. Gilead and Hennepin Healthcare will look at the safety and efficacy on moderate to severe cases COVID-19 in a FDA clinical study. It started on March 6 and has a primary completion date of May. Hennepin Healthcare expects results on the severe group in early May. "We are proud to be a site that's conducting research on this ... treatment," Jason Baker, MD, MS, Hennepin Healthcare Research Institute's primary investigator, said in a statement. "The clinical trials will help to determine if remdesivir is a safe and effective drug that can improve outcomes for patients diagnosed with COVID-19 here at Hennepin Healthcare and in the broader community."
Read the story on Pioneer Press.
Hennepin Healthcare and Mayo Clinic are participating in an international clinical trial on using the drug remdesivir to treat hospitalized COVID-19 patients. Gilead and Hennepin Healthcare will look at the safety and efficacy on moderate to severe cases COVID-19 in a FDA clinical study. "The clinical trials will help to determine if remdesivir is a safe and effective drug that can improve outcomes for patients diagnosed with COVID-19 here at Hennepin Healthcare and in the broader community," said Jason Baker, MD, MS, Hennepin Healthcare Research Institute’s primary investigator.
Read the story on Pioneer Press.
Kelley Baer’s schedule at the Shakopee women's correctional facility doesn’t change. Due to precautions made due to the COVID-19 pandemic, Baer’s days are stretching even longer. The gym is closed, inmates can only spend one hour outside each day, and the women are limited to 1.5 hours in the day room. “If there are strong measures in place already, like minimizing groups, isolating older or more sick patients in different parts of the prison, screening staff… it could be that the scope of coronavirus in facilities could be relatively small,” said Tyler Winkelman, MD, MSc, the co-director of the Health, Homelessness, and Criminal Justice Lab at Hennepin Healthcare Research Institute and a doctor at Hennepin County Jail. According to a notice sent to all DOC staff members, anyone who walks into a correctional facility must first be screened. That screening involves asking each staff member if they are showing symptoms such as a cough, and taking temperatures.
Read the story on Southwest News Media.
Upon hearing that a surge of COVID-19 cases could consume all hospital ventilators, Dr. Stephen Richardson rummaged for parts in the medical device lab at the University of Minnesota and built a homemade version. In a first test last week, the prototype kept a pig breathing for an hour and raised the prospect that low-budget ventilators could be built to solve a shortage. The makeshift ventilator was made from $150 in parts, with a motor ripped from another device and a red metal toolbox tray as its base. The university also is one arm of a multisite national trial of remdesivir, an experimental drug that failed in prior studies to treat infections from the Ebola and Marburg viruses. A third U-generated trial, awaiting FDA approval, would test whether a blood pressure-lowering medication, losartan, minimizes the damage of COVID-19. When infection stops ACE-2 receptors from working, there is a buildup of a hormone called angiotensin II that causes lungs to constrict and fluid to build up, explained Dr. Michael Puskarich, emergency physician at Hennepin Healthcare, who will be leading an arm of this trial at Hennepin Healthcare in downtown Minneapolis.
Read the article on Star Tribune.
Physicians and other health professionals are desperately needed during the global response to the COVID-19 pandemic. These individuals also represent one of the most at-risk populations for acquiring COVID-19. However, they face another risk: added stress. During these trying times, it is important to keep well-being in mind and address stress. “The impact of COVID-19 is overwhelming,” said AMA member Mark Linzer, MD, director of the Institute for Professional Work Life at Hennepin Healthcare and professor of medicine at the University of Minnesota in Minneapolis. “Everybody's wrestling with what's happening and what we can best do to take care of it.”
Read the AMA story.
The next site of a deadly coronavirus outbreak may not be a cruise ship, conference, or school. It could be one of America’s thousands of jails or prisons. Just about all the concerns about coronavirus’s spread in packed social settings apply as much, if not more, to correctional settings. In a prison, multiple people can be placed in one cell. Hallways and gathering places are often small and tight (often deliberately so, to make it easier to control inmates). There is literally no escape, with little to no space for social distancing or similar recommendations experts make to combat coronavirus. Hand sanitizer can be contraband. “We can learn what works in terms of mitigation from other countries who have seen spikes in coronavirus already, but none of those countries have the level of incarceration that we have in the United States,” Tyler Winkelman, MD, MSc, a doctor and researcher at Hennepin Healthcare and the University of Minnesota focused on health care and criminal justice, told me.
Read the story on Vox.
This week, a person incarcerated in King County Jail in downtown Seattle was taken to the hospital after they were suspected of having the new coronavirus. The county says there are no cases currently in the jail, but the new virus remains a huge concern for correctional facilities, particularly in outbreak hotspots like King County. With 85 confirmed cases of COVID-19, the illness caused by the virus, the county is home to the largest known hotspot of cases of the new coronavirus in the United States. It’s only a matter of time before the novel coronavirus enters a US jail or prisons, says Tyler Winkelman, MD, MSc, co-director of the Health, Homelessness, and Criminal Justice Lab at the Hennepin Healthcare Research Institute in Minneapolis. “All prisons and jails should anticipate that the coronavirus will enter their facility, and they need to have plans for monitoring and treating anyone who has symptoms,” he says.
Read the story on The Verge.
Dr. Hilden brings in special guest Dr. Anne Murray to talk the serious and important topic of dementia.
Listen to the Healthy Matters podcast.
Abbott announced that a high-sensitivity troponin I blood test used to detect MI has received FDA clearance. The blood test (Architect Stat) can detect very low levels of troponin, which allows physicians to assess patients within 2 to 4 hours of admission, according to a press release from the company. Results of the test are not affected by biotin interference, which is important as biotin supplements grow in popularity, according to the release. “The addition of Abbott’s high-sensitivity troponin I assay to the laboratory’s diagnostic testing menu is a great step forward to help laboratory scientists and clinicians better evaluate patients suspected of having a heart attack,” Fred. S. Apple, PhD, DABCC, co-director of the Clinical and Forensic Toxicology Laboratory at Hennepin Healthcare/Hennepin County Medical Center in Minneapolis and professor of laboratory medicine and pathology at the University of Minnesota in Minneapolis, said in the release.
Read the Healio story.
The U.S. Food and Drug Administration (FDA) cleared Abbott’s blood test to help aid in the diagnosis of heart attacks for men and women hours earlier than standard tests and marks significant progress for detecting heart attacks in women. Fred Apple, co-director of Clinical and Forensic Toxicology Laboratory at Hennepin Healthcare/Hennepin County Medical Center, said the addition of Abbott's high sensitivity troponin-I assay to the laboratory's diagnostic testing menu is a “great step forward to help laboratory scientists and clinicians better evaluate patients suspected of having a heart attack.”
Read the story on BioSpace.
Abbott announced today that new research, published in the journal Circulation, found its algorithm could help doctors in hospital emergency rooms more accurately determine if someone is having a heart attack or not, so that they can receive faster treatments or be safely discharged."With machine learning technology, you can go from a one-size-fits-all approach for diagnosing heart attacks to an individualized and more precise risk assessment that looks at how all the variables interact at that moment in time," said Fred Apple, Ph.D., Hennepin HealthCare/ Hennepin County Medical Center, professor of Laboratory Medicine and Pathology at the University of Minnesota, and one of the study authors. "This could give doctors in the ER more personalized, timely and accurate information to determine if their patient is having a heart attack or not."
Read the Yahoo Finance article.
Opioid addiction preventive vaccine would contain fentanyl hapten removing positive reaction to the drug. The University of Montana has received a $3.3 million contract from the National Institutes of Health (NIH) to develop an innovative vaccine targeting opioid addiction. The principal investigator on the 2-year award is Dr. Jay Evans, director of the University of Montana (UM)’s Center for Translational Medicine and a research professor in the Division of Biological Sciences. Other investigators on the award are Drs. David Burkhart, Kendal Ryter and Helene Bazin-Lee from UM in Missoula, Marco Pravetoni from the University of Minnesota, and Paul Pentel and Mark LeSage from Hennepin Healthcare Research Institute.
Read the Precision Vaccinations story.
Hennepin Healthcare Research Institute investigator Dr. Fred Apple, PhD, DABCC, discusses his article "Myocardial Infarction Risk Stratification With a Single Measurement of High-Sensitivity Troponin I" recently published in the Journal of the American College of Cardiology.
Read the interview on MedicalResearch.com
Gov. Tim Walz signed into law a response to Minnesota’s opioid crisis that he says holds Big Pharma accountable. In 2017, there were more than 2,000 visits to Minnesota emergency rooms for opioid-involved overdoses, with 422 Minnesotans losing their lives. Since 2010, the rate of opioid-related overdose deaths has steadily increased each year. The new law, championed in the Minnesota House by Rep. Liz Olson (DFL – Duluth), becomes effective immediately. The bill includes funding for Hennepin Healthcare’s “Project ECHO,” grants for tribal nations and urban Native-American communities, and additional staff for the Bureau of Criminal Apprehension’s drug labs and trafficking enforcement efforts. It also includes reforms to drug prescribing practices, improves efforts to safely remove excess drug supplies, and increases supplies of Naloxone (Narcan) for first responders.
Read the story on Insight News.
A new program is underway in Hennepin County to help inmates struggling with addiction. They are now screened for opioid use disorder when they arrive at the Adult Detention Center. It started in January to connect inmates with medication assisted treatment. “The folks that we’re seeing have been struggling with their substance use disorder for at least a year, but often 10, 15 or 20 years,” said Dr. Tyler Winkelman.
At Hennepin Healthcare, doctors read plenty of studies, but one that claims taking certain pills may increase your risk of dementia by as much as 50%, certainly stands out. Dr. Anne Murray works in geriatrics and conducts research of her own. She says the medical community has long suspected anticholinergic drugs, which are used to treat things like depression, Parkinson’s, incontinence, allergies and other conditions, may cause dementia later in life.
Mark Linzer, MD, Principal Investigator of the Healthy Work Place study, was interviewed on JNO Live about the study that shows trust is an important attribute to clinician satisfaction; identifies characteristics associated with gender, organizational climate. The live JAMA Network Open broadcast aired on Twitter, YouTube and Facebook.
The World Health Organization this week recognized burnout as an official medical diagnosis. "I think it's a really important thing that they've done this. I think that provides a foothold to begin the conversation about the workplace. What we can do to help," said Dr. Mark Linzer at Hennepin Healthcare. "Raises an important question. Now that we have a diagnosis, what can we do?"
Drug seizures for Minnesota's Violent Crime Enforcement Teams increased in several major drug categories in 2018. The increase in drug seizures corresponds with studies that have found a rise in drug use among Minnesotans and nationally. Dr. Tyler Winkelman of Hennepin Healthcare says research has shown that hospitalizations related to methamphetamine increased 270 percent nationally between 2008 and 2015.
Seizures of methamphetamine in Minnesota surged at an alarming level last year, as have confiscations of other illicit drugs, state public safety officials said, and a major bust already this year suggests the influx is not letting up. Dr. Tyler Winkelman, a physician and researcher at Hennepin Healthcare, said the “unintended consequences of getting rid of local meth labs with the crackdown on Sudafed” — the over-the-counter product that provides a key ingredient for making meth — is “that opened up the meth cartels from Mexico.”
What is the background for this study? What are the main findings?
Response: Kidney transplantation confers profound survival, quality of life, and cost benefits over dialysis for the treatment of end-stage kidney disease. Kidney transplant recipients under 65 years of age qualify for Medicare coverage following transplantation, but coverage ends after three years for patients who are not disabled.
Drug seizures for Minnesota’s Violent Crime Enforcement Teams (VCET) increased in several major drug categories in 2018, according to the Minnesota Department of Public Safety. The increase in drug seizures corresponds with studies that have found a rise in drug use among Minnesotans and nationally. According to research conducted by Dr. Tyler Winkelman of Hennepin Healthcare, hospitalizations related to methamphetamine increased nationally by 270 percent from 2008-2015, faster that any other form of substance abuse. The number of women using methamphetamine during pregnancy has increased significantly since 2008, particularly in rural areas.
Researchers from the University of Minnesota and Hennepin County hope to use a recent study regarding opioid-related deaths after incarceration to address the opioid epidemic. About one-third of opioid-related deaths in Hennepin County occurred within one year of inmates leaving jail, according to a report released by the county last month. Now, public health care officials and University researchers hope to offer care to incarcerated individuals with opioid use disorder based on the report’s recommendations. "Our workgroup made recommendations to begin treating people with opioid use disorders in county correctional facilities," said Tyler Winkelman, an author of the report, clinician-investigator with Hennepin Healthcare and assistant professor of medicine at the University. The treatment would include providing medications to incarcerated individuals with opioid use disorder and connecting them to community providers upon release.
New research by a local team of doctors is proving to be life-changing for people paralyzed by spinal cord injuries. It’s giving hope to thousands who previously thought they would never walk again. It took the University of Minnesota and Hennepin Healthcare two years to get through all of the paperwork, including grant approvals. It’s especially unique because doctors are studying patients who have been paralyzed for multiple years.
There are more than 290,000 people estimated to be living in the United States with a spinal cord injury. Previously, it has been shown that it is possible to restore some function to young and healthy patients within a few years of injury. Now, researchers show spinal cord stimulation can immediately restore some voluntary movement and autonomic functions such as cardiovascular, bowel, and bladder years after a paralyzing injury without any significant rehabilitation. "This was an opportunity to use epidural stimulation, combine my background in mathematics, collaborate with people from multiple disciplines including biomedical engineering and set up a truly innovative trial," said Dr. David Darrow, a neurosurgery resident at the University of Minnesota Medical School and a lead investigator for the E-STAND Clinical trial. He is also a senior neurosurgery resident at Hennepin Healthcare and University of Minnesota Medical Center.
There are more than 290,000 people estimated to be living in the United States with a spinal cord injury. Previously, it has been shown that it is possible to restore some function to young and healthy patients within a few years of injury. Now, researchers show spinal cord stimulation can immediately restore some voluntary movement and autonomic functions such as cardiovascular, bowel, and bladder years after a paralyzing injury without any significant rehabilitation. "This was an opportunity to use epidural stimulation, combine my background in mathematics, collaborate with people from multiple disciplines including biomedical engineering and set up a truly innovative trial," said Dr. David Darrow, a neurosurgery resident at the University of Minnesota Medical School and a lead investigator for the E-STAND Clinical trial. He is also a senior neurosurgery resident at Hennepin Healthcare and University of Minnesota Medical Center. "We wanted to push the envelope for patients. Once we determined it worked, we moved on to knocking down other barriers to translation to patient care."
Seasonal flu and other respiratory infections may be especially dangerous for kidney failure patients, researchers say. A new study found that influenza-like illnesses likely contribute to more than 1,000 deaths among kidney failure patients in the United States each year. These illnesses include potentially serious respiratory tract infections caused by flu and other viruses. For the study, David Gilbertson, co-director of the Chronic Disease Research Group at Hennepin Healthcare Research Institute in Minneapolis, and his colleagues reviewed 14 years of federal data.
Community activity for influenza-like illness (ILI) is associated with seasonal variation in all-cause mortality among patients with end-stage renal disease (ESRD), according to a study published online January 24 in the Journal of the American Society of Nephrology. David T. Gilbertson, PhD, from the Hennepin Healthcare Research Institute in Minneapolis, and colleagues calculated quarterly relative mortality compared with average third-quarter (summer) death counts after addressing overall increasing trends in death due to the growing prevalent ESRD population. Linear regression models were used to assess the correlation between ILI data and mortality.
In patients with kidney failure, influenza-like illness (ILI) likely contributes to more than 1,000 deaths per year. The finding, which comes from a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN), points to the importance of protection against, surveillance of, and, where possible, treatment of such infections in patients with kidney dysfunction.
The extent to which ILI contributes to mortality in patients with ESRD is unclear. To investigate, David Gilbertson, Ph.D. (Hennepin Healthcare Research Institute and the University of Minnesota) and his colleagues analyzed data from the Centers for Disease Control and Prevention Outpatient ILI Surveillance Network and the Centers for Medicare & Medicaid Services ESRD database from 2000-2013.
Flu-like illness contributed substantially to mortality for people with end-stage renal disease (ESRD), an analysis spanning 14 years of U.S. data indicated. During influenza season -- the 6 months from October to March -- excess deaths averaged more than 1,000 annually among the at-risk ESRD population, according to David Gilbertson, PhD, of the Hennepin Healthcare Research Institute and the University of Minnesota, and colleagues, pointing to influenza-like illness (ILI) as the likely reason.
Kristen Philman had already been using heroin and prescription painkillers for several years when, one day in 2014, a relative offered her some methamphetamine, a chemical cousin to the stimulant amphetamine. "I didn't have any heroin at the time," says Philman, a resident of Littleton, Colo. "I thought, 'Oh this might make me feel better.' "It did, she says. Soon, she was using both heroin and methamphetamine on a regular basis.
Committed to making physician burnout a thing of the past, the AMA has studied, and is currently addressing, issues causing and fueling physician burnout—including time constraints, technology and regulations—to better understand the challenges physicians face.
Mark Linzer, MD, director of the division of general internal medicine at Hennepin County Medical Center in Minneapolis, has long studied physician burnout.
“Burnout doesn’t have to be highly expensive to fix,” said Dr. Linzer, director of the HCMC Center for Patient and Provider Experience. “Preventing burnout can actually save money in the long run on recruiting and training new practice staff.”
The number of people hospitalized because of amphetamine use is skyrocketing in the United States, but the resurgence of the drug has largely been overshadowed by the nation’s intense focus on opioids.
Amphetamine-related hospitalizations jumped by about 245 percent from 2008 to 2015, according to a study published last month in the Journal of the American Medical Association. That dwarfs the rise in hospitalizations from other drugs, such as opioids, which were up by about 46 percent. The most significant increases were in Western states.
The JAMA study, based on hospital discharge data, found that the cost of amphetamine-related hospitalizations had jumped from $436 million in 2003 to nearly $2.2 billion by 2015. Medicaid was the primary payer.
For those with a substance use disorder, the risk of death from an overdose in the two weeks after leaving prison is 10 times higher than in the general population, said Dr. Tyler Winkelman of the Minneapolis-based Hennepin Healthcare, who researches health
issues in the criminal justice system.
Because there has been so much attention on opioids, “we have not been properly keeping tabs on other substance use trends as robustly as we should,” said study author Dr. Tyler Winkelman, a physician at Hennepin Healthcare in Minneapolis.
The number of people hospitalized because of amphetamine use is skyrocketing in the United States, but the resurgence of the drug largely has been overshadowed by the nation’s intense focus on opioids.
The number of people hospitalized because of amphetamine use is skyrocketing in the United States, but the resurgence of the drug largely has been overshadowed by the nation’s intense focus on opioids. Amphetamine-related hospitalizations jumped by about 245% from 2008 to 2015, according to a recent study in the Journal of the American Medical Association.
11 a.m. – MPR News at 11
An estimated 30,000 people died from opioid overdoses in the U.S. in 2017. With so many people being affected what is being done to treat addiction?
Dr. Diana Cutts, a pediatrician from Hennepin Healthcare, part of the FoodRx program, said the dilemmas poor families face are real and wrenching.
“One of the problems with addiction treatment is that it’s generally been put on the patient to take care of on their own. We wouldn’t tell someone with cancer or heart disease to go make an appointment and hope they get better,” said Dr. James Miner, chief of emergency medicine at HCMC. “The goal now is to get people started on treatment and on the road to recovery right away.”
Aspirin has been a top topic all week — in clinics, living rooms and offices — because
three studies challenged the guidance for certain older adults taking it daily.
The latest study, known as ASPREE, followed 15,000 healthy adults ages 70 and older
over five years. It found that those taking aspirin had no greater protection from
disabilities or heart attacks but did have higher drug-related risks of internal bleeding.
Margolis and Bloomington-based HealthPartners enrolled 250 adults. Minneapolis-based
Hennepin Healthcare led the U.S. arm of the study, which was based in Australia.
Dr. Anne Murray, the Hennepin geriatrician who led the research, has been flooded with
questions about her results: “It’s been a combination of patients and colleagues, some of
whom are taking aspirin themselves.”
Many older people who’ve survived a heart attack or stroke take low-dose aspirin every day to help prevent further cardiovascular problems . There is compelling evidence that this works. But should perfectly healthy older folks follow suit?
Most of us would have guessed “yes”—but the answer appears to be “no” when you consider the latest scientific evidence. Recently, a large, international study of older people without a history of cardiovascular disease found that those who took a low-dose aspirin daily over more than 4 years weren’t any healthier than those who didn’t. What’s more, there were some unexpected indications that low-dose aspirin might even boost the risk of death.
The long-awaited results of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, partly funded by NIH, were presented in three papers just published in the New England Journal of Medicine [2,3,4]. It’s the largest primary prevention study ever undertaken in healthy older people.
To take a closer look, a research team led by John McNeil, Monash University, Melbourne, Australia, and Anne Murray, Hennepin Healthcare Research Institute, Minneapolis, launched the ASPREE trial in 2010.
A major international study led in part by a Minnesota physician has found that healthy
people over age 70 got no preventive benefit from aspirin and were at greater risk for
harm such as stomach bleeding. It's the third major study this year to reach a similar
"We hope this shifts the paradigm for people 70 and older who are considering taking
aspirin," said Dr. Anne Murray, a geriatrician at Hennepin Healthcare in Minneapolis
who led the research along with Dr. John McNeil in Australia.
Many heart-healthy older people take a daily baby aspirin out of a belief that it will help prevent a
heart attack or stroke. A major new study, published online Sunday in three articles in the New England Journal of Medicine (NEJM), now calls that common practice into serious question. It found that for older people with no history of heart attack, stroke or congestive heart failure taking a daily aspirin might do more harm than good.
”We found there was no discernible benefit of aspirin on prolonging independent, healthy life for the elderly,” Dr. Anne Murray, one of the authors of the study and an epidemiologist and geriatrician at Hennepin Healthcare in Minneapolis, told National Public Radio (NPR) reporter Rob Stein.
Read the MinnPost story
In healthy elderly people who never had a heart attack, the widespread practice of taking a baby aspirin every day may do more harm than good, according to a U.S.-Australian study of more than 19,000 volunteers.
The results - which show that risks of major bleeding in low-dose aspirin users overwhelm any heart benefits - were reported online in the New England Journal of Medicine and presented Sunday at the European Respiratory Society International Congress in Paris.
Read the Reuters story on FOX NEWS
It's one of the most well-known tenets of modern medicine: An aspirin a day keeps the doctor away. But according to a trio of studies published Sunday in the New England Journal of Medicine, a daily low-dose aspirin regimen provides no significant health benefits for healthy older adults. Instead, it may cause them serious harm.
Should older people in good health start taking aspirin to prevent heart attacks, strokes,
dementia and cancer?
No, according to a study of more than 19,000 people, including whites 70 and older, and
blacks and Hispanics 65 and older. They took low-dose aspirin — 100 milligrams — or a
placebo every day for a median of 4.7 years. Aspirin did not help them — and may have
Read the story in The New York Times
The possible utility of aspirin for primary prevention has taken another blow with new results showing no benefit of treatment in extending disability-free survival, a novel endpoint that combines all-cause death, dementia, or physical disability, among healthy elderly persons.
A second report showed no significant reduction in cardiovascular disease but a significantly higher risk for major hemorrhage, and a third analysis showed higher all-cause mortality with aspirin therapy, mostly attributed to increased cancer risk, although the researchers urge caution in interpreting this latter finding.
The results, from the Aspirin in Reducing Events in the Elderly (ASPREE) trial, were published online September 16 in three separate papers in the New England Journal of Medicine (NEJM).
Many healthy Americans take a baby aspirin every day to reduce their risk of having a heart attack, getting cancer and even possibly dementia. But is it really a good idea?
Results released Sunday from a major study of low-dose aspirin contain a disappointing answer for older, otherwise healthy people.
"We found there was no discernible benefit of aspirin on prolonging independent, healthy life for the elderly," says Anne Murray, a geriatrician and epidemiologist at Hennepin Healthcare in Minneapolis, who helped lead the study.
A regimen of low-dose aspirin “offers healthy, older people no benefit in staving off cardiovascular disease, dementia or disability and increases their risk of bleeding in the digestive tract and brain, according to a large study released Sunday.” The article says that research indicates “a regimen of low-dose aspirin offers healthy, older people no benefit in staving off cardiovascular disease, dementia or disability and increases their risk of bleeding in the digestive tract and brain.” The findings were published in three articles in the New England Journal of Medicine. In a news release, Richard J. Hodes, Director of the National Institute on Aging, said, “Clinical guidelines note the benefits of aspirin for preventing heart attacks and strokes in persons with vascular conditions such as coronary artery disease.” Hodes added, “The concern has been uncertainty about whether aspirin is beneficial for otherwise healthy older people without those conditions.” To view the NEJM articles, click here, here, and here.
Researchers determined that after nearly five years in treatment, participants’ “rate of heart disease was not significantly lower,” although the “rate of major bleeding with daily aspirin use was 3.8 percent, versus 2.8 percent with placebo.” Lead author Dr. John J. McNeil of Monash University commented, “Essentially, we could not identify any subgroup in whom aspirin was beneficial in preserving good health.”
For decades, a daily dose of aspirin has been widely considered a way to protect healthy people from cardiovascular disease and even cancer. But a large international study finds that even at low doses, long-term use of aspirin may be harmful — without providing any benefit — for older people who have not already had a heart attack or stroke.
The new research reinforces the results of a study published in late August, which found that daily low-dose aspirin was too risky to be prescribed to patients at moderate risk of heart disease. In the August study and the new one, researchers found a significant risk of internal gastric bleeding caused by the medication, which thins the blood. Older patients experienced no health benefits from taking aspirin, according to the new report, published Sunday in the New England Journal of Medicine.
“We knew there would an increased risk of bleeding with aspirin, because there has always been," said study coauthor Dr. Anne Murray, a geriatrician and epidemiologist at the Hennepin Healthcare Research Institute and the University of Minnesota, Minneapolis. "But not only did it not decrease risk of disability or death, it did not decrease the risk of heart attack and stroke, and there was an increase in the rate of death."
Another clinical trial has added more evidence against the fairly common practice of prescribing aspirin to healthy older adults in order to prevent the onset of cardiovascular disease.
The clinical trial, which ran from 2010 to 2014 and included 19,114 individuals 70 years and older from the U.S. and Australia, found that a low daily dose of aspirin only marginally decreased a patient's risk of cardiovascular disease while significantly increasing the patient's risk of hemorrhage. Additionally, higher death rates were reported among those taking aspirin daily although the researchers are skeptical about how much weight to put on the finding since it's an unexpected outcome compared to similar studies.
"For a healthy person 70 and older who doesn't have an indication to be on aspirin, there really is no benefit to be on aspirin, in fact, the risks appear to outweigh the benefits in terms of increase bleeding risk and the potential for increased mortality risk," said Dr. Anne Murphy, co-principal investigator of the trial and director of the Berman Center for Outcomes and Clinical Research.
Millions of healthy people who take aspirin to ward off illness in old age are unlikely to
benefit from the drug, a trial has found.
While a daily dose of the blood-thinning medicine can protect older people who have
previously experienced heart attacks, strokes and angina, researchers found the drug did
not extend the lifespan of healthy people over the age of 70.
Doctors in Australia and the US enrolled more than 19,000 healthy people, mostly aged
over 70, for the trial. Half the participants were asked to take 100mg of aspirin each day,
while the rest took a placebo pill.
People addicted to prescription opioids or heroin are far more likely to have run-ins with the
law than those who don't use opioids, according to a new study published Friday in JAMA
"There have been reports that jails and prisons are bearing the brunt of the opioid epidemic,
but we didn't know nationally how many people who use opioids are involved in the criminal
justice system," says Tyler Winkelman, a clinician-investigator at Hennepin Healthcare in Minneapolis, and lead author of the study.
Providing integrated medical care and social support services led to increased use of
primary care among vulnerable adults who were enrolled in a Medicaid accountable
care organization (ACO), according to two studies published in Medical Care Research
One study used Medicaid claims data for about 90,000 enrollees to compare the use of
medical services by Hennepin Health (Hennepin County, MN) ACO enrollees to non-ACO
Medicaid enrollees in the same geographic area.
The second study used interview data from 35 Hennepin Health members enrolled for two or more years during the study period.
People take a vaccine for the flu every year to avoid getting sick, but researchers across the country are working on a vaccine to help opioid addicts avoid overdosing.
"Ultimately, I think it can save lives. A vaccine like this could offer sort of long lasting protection," said senior investigator at the Minneapolis Medical Research Foundation (MMRF) Dr. Marco Pravetoni. Pravetoni and his team at MMRF have been working on a vaccine for the last 10 years, with their primary focus on the prescription painkiller oxycontin.
Read the CircaNews story